Abstract
Taiwan's National Health Insurance has covered targeted therapy, namely cetuximab, for locally advanced head and neck cancers (LAHNC) since July 2009. This study aimed to estimate the trends of first-course treatment modalities before and after cetuximab was reimbursed in Taiwan and examine factors associated with targeted therapy among patients with LAHNC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have